Motiva SmoothSilk Round Ergonomix Silicone Gel-Filled Breast Implants, Motiva SmoothSilk Round Silicone Gel-Filled Breas
Motiva USA, LLC · Decision date Oct 2, 2026
What did the FDA approve?
FDA approved supplement S002 to PMA P230005 for Motiva SmoothSilk Round Ergonomix and Motiva SmoothSilk Round silicone gel-filled breast implants. The decision, dated October 2, 2026, is an approval for a product line extension to smaller size devices. The supplement type is a Normal 180 Day Track, and the stated reason is a change in design, components, specifications, or material.
The device is classified as a noninflatable, internal, silicone gel-filled breast prosthesis under product code FTR, in the general and plastic surgery specialty. The applicant is Motiva USA, LLC. The source statement does not include specific smaller sizes, dimensional specifications, or clinical data. A supplement approval does not represent a new approval of the entire PMA system.
FDA approval order statement
Approval for the product line extension to smaller size devices
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 2, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230005/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Motiva USA, LLC
- Product code
- FTR
- Decision code
- APPR
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, breast, noninflatable, internal, silicone gel-filled.
- Applicant
- Motiva USA, LLC
- Product code
- FTR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230005 · Original PMA
Motiva SmoothSilk Round Ergonomix Silicone Gel-Filled Breast Implants, Motiva SmoothSilk Round Silicone Gel-Filled Breas
P230005/S002 received
Application receipt date recorded by FDA.
P230005/S005 · Related supplement
Motiva SmoothSilk Round and Round Ergonomix Silicone Gel-Filled Breast Implants
P230005/S002 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P230005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Motiva USA, LLC | PMA approval | Sep 26, 2024 | FDA | |
| Motiva USA, LLC | PMA supplement | Sep 25, 2026 | FDA |
Explore the linked device profile
Other records with product code FTR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Sientra Silicone Gel Breast ImplantsP070004/S049 | Tiger Aesthetics Medical, LLC | PMA supplement | Nov 4, 2026 | FDA |
MemoryGel Breast ImplantsP030053/S093 | Mentor Corp. | PMA supplement | Oct 23, 2026 | FDA |
MemoryShape Breast ImplantsP060028/S063 | Mentor Worldwide, LLC | PMA supplement | Oct 23, 2026 | FDA |
| Allergan | PMA supplement | Sep 29, 2026 | FDA | |
| Mentor Worldwide, LLC | PMA approval | Jun 14, 2013 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Motiva USA, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2543 Mesa School Ln., Santa Barbara, CA, 93109
Sources and methodology
- Original FDA record: P230005/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



